NCT00221195View on ClinicalTrials.gov

Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions
Hemophilia A With Inhibitors
Interventions
DRUG

activated prothrombin complex concentrate (FEIBA)

"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"

Trial Locations (1)

70112

Tulane University School of Medicine, New Orleans

All Listed Sponsors
lead

Tulane University School of Medicine

OTHER

NCT00221195 - Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors | Biotech Hunter | Biotech Hunter